Introduction {#s1}
============

Coronary atherosclerotic heart disease is a heart disease caused by myocardial ischemia, hypoxia, or necrosis. Its underlying cause is that coronary atherosclerosis causes stenosis, spasm, or obstruction of the coronary lumen. They are collectively referred as coronary heart disease (CHD) or coronary artery disease, called CHD for short ([@B5]). In recent years, the morbidity and prevalence rate of coronary disease in China has been increasing significantly, especially the young people's death of coronary disease gets more and more attention ([@B35]; [@B37]). According to the research data of the Lancet in 2013, the death rate of CHD in China increased by 31.6% from 1990 to 2010, and CHD rose from the seventh place to the second place in the list of causes of premature death in China ([@B39]). CHD can affect the quality of life of patients severely, for example, the incidence of sudden death in people with a record of CHD attack is 4 or 6 times higher than that in the general population ([@B15]). With the trend of patients being young, the possibility of disability in patients with CHD is also significantly increased. At the same time, all kinds of medical costs of CHD are enormous because of a long course, a low cure rate, and a high recurrence rate. In China, the average cost of interventional therapy for CHD is about 40,000 to 60,000 CNY per time, and the cost of coronary artery bypass grafting is about 40,000 to 100,000 CNY ([@B24]).

Salvia miltiorrhiza and its compound preparations have the effect of improving blood flow, activating blood circulation to dissipate blood stasis ([@B43]; [@B36]). Known as Danshen, they have been used in China for a long history with a wide variety and a large amount of consumption. They are extensively used in the treatment of cardiovascular diseases, such as CHD, angina pectoris, hyperlipidemia, and acute ischemic stroke ([@B34]). In Japan, the United States, and some European countries, products of Salvia miltiorrhiza also can be obtained.

Traditional Chinese medicine injections (TCMIs) are produced from herbals using modern techniques and have been widely used in the clinic in China ([@B7]). Salvianolate injection is one of the most extensive prescription drugs used in the treatment of cardiovascular disease since it was launched in 2005 in China. Some TCMIs may contain multiple unknown compounds, but the components of salvianolate injection were clarified, which may lead to less severe anaphylaxis. Some clinical trials and systematic evaluations have confirmed that salvianolate injection can substantially improve the clinical symptoms of patients with CHD ([@B30]; [@B23]; [@B22]), and can reduce the angina attacks with functional safety, low incidence of adverse drug reactions ([@B16]; [@B10]; [@B11]; [@B41]), which shows that salvianolate injection is well tolerated in the general population ([@B38]).

However, there are few clinical and economic evaluations of salvianolate injection in real-world practice. Some retrospective studies had compared salvianolate injection with other salvia miltiorrhiza injections ([@B19]; [@B40]; [@B28]). Nevertheless, in clinical practice, doctors tend to choose drugs on consideration of patients' actual conditions. Therefore, to evaluate the clinical and economic effects of specific Chinese medicine products must consider realistic comparator drugs ([@B31]). In current literature, the evaluation of curative effect and economic benefit of the salvianolate injection with the comparison of other Chinese medicine products and chemical drugs for CHD patients in the real clinical environment is still lacking ([@B9]).

In current clinic practice, Danhong injection is a useful clinical medication for CHD and angina. It has a good curative effect with little adverse reaction ([@B42]; [@B29]; [@B21]). Besides, alprostadil injection can significantly improve myocardial microcirculatory disturbance and hemorheological disorder in patients with CHD, which is also used for CHD in the current clinic ([@B12]). However, in the literature, there are few comparative economic and clinical evaluation of Chinese patent medicine and chemical medicine in the treatment of CHD.

Therefore, this study aimed to conduct clinical and economic evaluation of salvianolate injection for patients with CHD in comparison to Danhong injection and alprostadil injection. It is expected that the findings can provide evidence for clinical treatment for CHD.

Methods {#s2}
=======

Composition Information {#s2_1}
-----------------------

On 25^th^ May 2015, salvianolate injection was approved by the State Food and Drug Administration (SFDA) of China as a new drug (Batch Number: Z20050247-49). First authorized on 4^th^ June 2007 to the Shanghai Green Valley Pharmaceutical Co, Ltd to manufacture, salvianolate injection was renewed on 15^th^ July 2016 by SFDA.

### Botanical {#s2_1_1}

The species was named as Salvia miltiorrhiza Bunge (Family: Lamiaceae Martinov, Genus: Salvia L.), which is accepted by the Kew Medicinal plant names service, and its native range is Central & S. China to Vietnam ([@B14]). First published in Enum. Pl. China Bor.: 50 (1833), Salvia miltiorrhiza Bunge (Bge.) was cited by a lot of medicinal references such as Pharmacopoeia of China (2015), British Pharmacopoeia 2015, Vol. 4 (2014), U.S. Pharmacopoeia USP 39 (2016), and U.S. FDA Substance Registration System (2016) ([@B1]; [@B7]; [@B33]; [@B32]).

### Chemical {#s2_1_2}

Salvianolate injection is a traditional Chinese medicine injection identified by the SFDA, containing major homologues such as salvianolic acid B (≥85%), rosemary acid (≥10.1%), and lithospermic acid (≥1.9%).

Since the early 1930s, China has begun to study the chemical composition of salvia miltiorrhiza. However, these early studies focused on lipophilic compounds ([@B43]). With the support of the Chinese Academy of Sciences and the Ministry of Science and Technology of PRC, the Shanghai Institute of Materia Medica found that the water-soluble active ingredients of salvia miltiorrhiza existed in the form of salts. Through active screening and pharmacological studies, it was found that active compounds are mainly salvianolic acid B and homologs, such as rosemary acid, lithospermic acid, dansensu, salvianolic acid B, tanshinone IIA, and dimethyl lithospermate ([@B2]; [@B13]; [@B20]), among which salvianolic acid B had the strongest pharmacological effect. It was also clarified that salvianolic acid B was the most important active ingredients of salvia miltiorrhiza in the treatment of cardiovascular diseases. A method for extracting and purifying chemical constituents from salvia miltiorrhiza by ethanol extraction method was well established, related technologies have been approved as Chinese patents and United States patents.

Target Population and Data Source {#s2_2}
---------------------------------

The target population of this study is CHD patients who were followed up from the first inpatient treatment in 2015 to December 31, 2015. The data was collected from the National Urban Basic Medical Insurance Database at the China Medical Insurance Research Association. China Medical Insurance Research Association is a national, semi-official organization that is directly managed by the National Healthcare Security Administration of China. With the official support of the National Healthcare Security Administration of China, China Medical Insurance Research Association establishes and maintains the National Urban Basic Medical Insurance Database that regularly and systematically collects the reimbursement data of social insurance from all the provincial governments in China ([@B6]). Therefore, the National Urban Basic Medical Insurance Database at the China Medical Insurance Research Association is one of the most reliable databases for retrospective study in China.

The specific inclusion criteria of the patients are:

1.  Patient who diagnosed with CHD for the first time before September 30, 2015;

2.  CHD was the principal diagnosis (identification terms: angina pectoris, CHD, coronary artery, atherosclerosis, cardiac or myocardial infarction, ICD-10 code: I20-I25) when discharged from inpatient department and frequency of visits occurred before September 30, 2015.

The specific exclusion criteria of the patients are:

1.  Patients who younger than or equal to 18 years old;

2.  Patients with malignant tumors or schizophrenic patients or patients on dialysis.

Treatment and Grouping {#s2_3}
----------------------

All patients were divided into exposed group and control group. The exposed group was hospitalized with salvianolate injection, and the control group was treated with Danhong injection or alprostadil injection. The outcomes of salvianolate injection and Danhong injection, salvianolate injection, and alprostadil injection were compared.

-   Salvianolate Injection Group

    The principal diagnosis during hospitalization was CHD and was prescribed salvianolate injection while alprostadil injection and other traditional Chinese medicine injections of blood-activating and stasis-dissolving are not prescribed.

-   Danhong Injection Group

    The principal diagnosis during hospitalization was CHD and was prescribed Danhong injection while alprostadil injection and other traditional Chinese medicine injections of blood-activating and stasis-dissolving are not prescribed.

-   Alprostadil Injection Group

    The principal diagnosis during hospitalization was CHD and was prescribed alprostadil injection while other traditional Chinese medicine injections of blood-activating and stasis-dissolving are not prescribed.

Study Perspective and Cost {#s2_4}
--------------------------

This study chose a perspective of medical insurance payer. All the costs were only based on the reimbursement records of medical insurance. Compared with the medical record data at hospitals, the insurance claim data in China has few risk and cost parameters. Therefore, this study focused on the medical costs per hospitalization because this data is most reliable data to reflect the economic effectiveness of treatments.

Outcomes {#s2_5}
--------

The outcome indicators of this study include medical cost per hospitalization, hospitalization duration, 10d re-hospitalization rate, 30d re-hospitalization rate, and 90d re-hospitalization rate. Their definitions are listed below:

-   10d Rehospitalization Rate: refers to the proportion of inpatients with CHD who re-hospitalized within 10 days of the total number of hospitalized patients in this group after the first hospitalization. (If there are more than one readmission for CHD, counted as rehospitalization)

-   30d Rehospitalization Rate: refers to the proportion of inpatients with CHD who re-hospitalized within 30 days of the total number of hospitalized patients in this group after the first hospitalization. (If there are more than one readmission for CHD, counted as rehospitalization)

-   90d Rehospitalization Rate: refers to the proportion of inpatients with CHD who re-hospitalized within 90 days of the total number of hospitalized patients in this group after the first hospitalization. (If there are more than one readmission for CHD, counted as rehospitalization)

Bias and Elimination {#s2_6}
--------------------

The primary bias of this study was the selection bias. Thus, the Propensity Score Matching (PSM) method was used to control the confounding factors and reduce the impact of confounding factors on the intervention effect estimation.

In this study, the surgery sample was covariate based on age, gender, region, level of medical institution, whether combined with stroke, whether nitrate esters are prescribed (ATC code: XC01DA), whether nitrate esters are prescribed (ATC code: XB01AD), whether percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) was used. The matching ratio is 1:1, and the caliper value is 0.05. Furthermore, the non-surgery sample was covariate based on age, gender, region, level of medical institution, whether combined with stroke, whether nitrate esters are prescribed (ATC code: XC01DA), whether nitrate esters are prescribed (ATC code: XB01AD). The matching ratio is 1:1, and the caliper value is 0.05.

Heterogeneity {#s2_7}
-------------

In order to avoid or reduce the impact of disease severity on the results, stratified analysis was adopted in this study to divide the population of CHD patients into surgery sample and non-surgery sample according to whether they had received surgery during hospitalization, and the difference of outcome indicators between the exposure group and the two control groups was analyzed in each sample.

Statistical Analysis {#s2_8}
--------------------

Descriptive analysis: measurement data are described by mean ± standard deviation (x ± s) or median and quartile, and enumeration data are described by frequency and rate.

Single factor analysis: For measurement data, the indicators of exposure group and control group were compared, T-test was used to compare the indicators between the exposed group and the control group which obeyed the normal distribution, Wilcoxon rank sum test was used to compare the two groups of indicators that did not obey the normal distribution. For enumeration data, Chi-square test was used. For all the above, *P* \< 0.05 was considered statistically significant.

Multiple-factor analysis: Multivariate linear regression model was used for the dependent variable of hospitalization cost per hospitalization and hospitalization duration. If the dependent variable did not obey normal distribution, then run a natural logarithmic transformation. If the variance was not homogeneous, then do robust regression adjustment.

Results {#s3}
=======

In this study, 2,473 patients with CHD who met the inclusion and exclusion criteria were included, including 541 patients in the surgery sample and 1,932 patients in the non-surgery sample. The flowchart of sampling and grouping are summarized in [**Figure 1**](#f1){ref-type="fig"}.

![Flowchart of sampling and grouping. The unit in the figure is per person.](fphar-11-00887-g001){#f1}

Baseline Characteristics of the Total Sample {#s3_1}
--------------------------------------------

The difference between the surgery sample and the non-surgery sample is statistically significant in the following variables: age, gender, level of medical institutions, regional distribution, whether comorbid with high blood pressure or heart failure or diabetes, whether combine medication with beta blockers or nitrate esters or angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) or antiplatelet/thrombolytic/anticoagulant or lipid-regulating drugs.

Among them, the age of the non-surgery sample is slightly higher than that of the surgery sample. There are more males in the surgery sample than in the non-surgery sample. The surgery sample mainly distributes in tertiary hospitals and eastern region, while the non-surgery sample mainly distributes in secondary and grass-roots hospitals and central and western region. The proportion of patients with high blood pressure, heart failure, and diabetes in the surgery sample was higher than that in the non-surgery sample, and the proportion of patients with drugs combined in the surgery sample was higher than that in the non-surgery sample except for calcium channel blockers. Among the hospitalized patients with CHD, 170 patients had undergone CHD related surgery (PCI/CABG), accounting for 6.9% (as shown in [**Table 1**](#T1){ref-type="table"}).

###### 

Overall baseline characteristics of hospitalized patients with CHD.

  Variable                                   Total         Surgery sample   Non-surgery sample   *Z/χ^2^*   *P*                      
  ------------------------------------------ ------------- ---------------- -------------------- ---------- -------- ------ -------- ---------
  Age, P~50~ (P~25~-P~75~)                   68 (60--76)   67 (60--74)      68 (60--77)          2.39       0.0168                   
  Gender                                                                                                                    56.14    \<0.001
   Male                                      1225          49.5             345                  63.8       880      45.6            
   Female                                    1248          50.5             196                  36.2       1052     54.5            
  Level of medical institutions                                                                                             206.46   \<0.001
   Tertiary hospital                         1006          40.7             359                  66.4       647      33.5            
   Secondary hospital                        1022          41.3             157                  29.0       865      44.8            
   Primary hospital                          445           18.0             25                   4.6        420      21.7            
  Region                                                                                                                    52.21    \<0.001
   Eastern region                            1046          42.3             301                  55.6       745      38.6            
   Central region                            1187          48.0             192                  35.5       995      51.5            
   Western region                            240           9.7              48                   8.9        192      9.9             
  Comorbidity                                                                                                                        
   High blood pressure                       700           28.3             205                  37.9       495      25.6   31.36    \<0.001
   Heart failure                             163           6.6              50                   9.2        113      5.9    7.90     0.0050
   Atrial fibrillation                       50            2.0              7                    1.3        43       2.2    1.85     0.1735
   Heart valve disease                       9             0.4              4                    0.7        5        0.3    2.69     0.1009
   Stroke                                    181           7.3              43                   8.0        138      7.1    0.40     0.5250
   Pulmonary embolism                        6             0.2              0                    0.0        6        0.3    1.68     0.1944
   COPD                                      38            1.5              8                    1.5        30       1.6    0.02     0.9015
   chronic nephrosis                         27            1.1              8                    1.5        19       1.0    0.96     0.3271
   Diabetes                                  643           26.0             215                  39.7       428      22.2   67.95    0.0001
  Drug combination                                                                                                                   
   Beta blockers                             1182          47.8             342                  63.2       840      43.5   65.99    0.0001
   Nitrate esters                            1932          78.1             506                  93.5       1426     73.8   96.18    0.0001
   ACEI or ARB                               1141          46.1             307                  56.8       834      43.2   31.36    0.0001
   Calcium antagonist                        922           37.3             199                  36.8       723      37.4   0.07     0.7860
   Antiplatelet/thrombolytic/anticoagulant   1428          57.7             476                  88.0       952      49.3   259.55   0.0001
   Lipid regulating agents                   1817          73.5             473                  87.4       1344     69.6   69.21    0.0001
  Related surgery of CHD                                                                                                             
   PCI/CABG                                  170           6.9              170                  31.4                                

Surgery Sample: Salvianolate Injection and Danhong Injection {#s3_2}
------------------------------------------------------------

### Baseline Characterization {#s3_2_1}

After stratified analysis and PSM, 114 pairs of matched patients were obtained. In the surgery sample, the salvianolate injection group and the Danhong injection group were all 114 patients. There were statistically significant differences in the distribution of beta blockers and ACEI or ARB drugs between the two groups. The differences between the two groups were not statistically significant in the following variables: age, gender, level of medical institutions, regional distribution, whether comorbid with other diseases, whether combine medication with other drugs and whether had undergone CHD related surgery (as shown in [**Table 2**](#T2){ref-type="table"}).

###### 

Baseline characteristics of salvianolate injection group and Danhong injection group in the surgery sample.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                   Total         Salvianolate injection group   Danhong injection group   *Z/χ^2^*   *P*                    
  ------------------------------------------ ------------- ------------------------------ ------------------------- ---------- -------- ------ ------ --------
  Age, P~50~ (P~25~-P~75~)                   65 (59--72)   65 (59--72)                    65 (60--72)               −0.27      0.7870                 

  Gender                                                                                                                                       1.97   0.1601

   Male                                      152           66.7                           81                        71.1       71       62.3          

   Female                                    76            33.3                           33                        29.0       43       37.7          

  Level of medical\                                                                                                                            0.02   0.9895
  Institutions                                                                                                                                        

   Tertiary hospital                         151           66.2                           76                        66.7       75       65.8          

   Secondary hospital                        69            30.3                           34                        29.8       35       30.7          

   Primary hospital                          8             3.5                            4                         3.5        4        3.5           

  Region                                                                                                                                       0.24   0.8873

   Eastern region                            102           44.7                           52                        45.6       50       43.9          

   Central region                            106           46.5                           53                        46.5       53       46.5          

   Western region                            20            8.8                            9                         7.9        11       9.7           

  Comorbidity                                                                                                                                         

   High blood pressure                       76            33.3                           38                        33.3       38       33.3   0.00   1.0000

   Heart failure                             20            8.8                            9                         7.9        11       9.7    0.22   0.6396

   Atrial fibrillation                       2             0.9                            1                         0.9        1        0.9    0.00   1.0000

   Heart valve disease                       1             0.4                            1                         0.9        0        0.0    1.00   0.3162

   Stroke                                    14            6.1                            6                         5.3        8        7.0    0.30   0.5811

   Pulmonary embolism                        0             0.0                            0                         0.0        0        0.0    \\     

   COPD                                      2             0.9                            1                         0.9        1        0.9    0.00   1.0000

   Chronic nephrosis                         2             0.9                            2                         1.8        0        0.0    2.02   0.1555

   Diabetes                                  74            32.5                           38                        33.3       36       31.6   0.08   0.7773

  Drug combination                                                                                                                                    

   Beta blockers                             141           61.8                           63                        55.3       78       68.4   4.18   0.0409

   Nitrate esters                            209           91.7                           108                       94.7       101      88.6   2.81   0.0935

   ACEI or ARB                               114           50.0                           49                        43.0       65       57.0   4.49   0.0341

   Calcium antagonist                        80            35.1                           36                        31.6       44       38.6   1.23   0.2669

   Antiplatelet/thrombolytic/anticoagulant   202           88.6                           103                       90.4       99       86.8   0.69   0.4046

   Lipid regulating agents                   200           87.7                           99                        86.8       101      88.6   0.16   0.6865

  Related surgery of CHD                     69            30.3                           37                        32.5       32       28.1   0.52   0.4710
  ------------------------------------------------------------------------------------------------------------------------------------------------------------

### Single-Factor Analysis of Outcome Indicators {#s3_2_2}

In the surgery sample, between the salvianolate injection group and Danhong injection group, there were no significant differences in hospitalization duration, 10d rehospitalization rate, 30d rehospitalization rate, 90d rehospitalization rate, and the medical cost per hospitalization (as shown in [**Table 3**](#T3){ref-type="table"}).

###### 

Comparison of outcomes of salvianolate injection group and Danhong injection group in the surgery sample.

  Variable                            Total      Salvianolate injection group   Danhong injection group   *Z/χ^2^*   *P*                                                    
  ----------------------------------- ---------- ------------------------------ ------------------------- ---------- -------- --------- --------- -------- --------- ------ --------
  Average days of per hospital stay   10         7                              12                        9          6        11        10        7        13        1.77   0.0766
  10d rehospitalization rate, n (%)   3 (1.3)    0 (0.0)                        3 (2.6)                   3.04       0.0812                                                 
  30d rehospitalization rate, n (%)   9 (4.0)    4 (3.5)                        5 (4.4)                   0.12       0.7338                                                 
  90d rehospitalization rate, n (%)   20 (8.8)   13 (11.4)                      7 (6.1)                   1.97       0.1601                                                 
  Medical costs per hospitalization   13170.3    8465.4                         42342.5                   12900.5    8208.5   42611.6   13578.2   8591.1   42073.4   0.41   0.6784

### Multi-Factor Analysis of Outcome Indicators {#s3_2_3}

For multiple linear regression models to control potential confounding factors such as age, gender, medical institution level, and comorbidities, in the surgery sample, there was no significant difference between two groups in terms of hospitalization duration.

Surgery Sample: Salvianolate Injection and Alprostadil Injection {#s3_3}
----------------------------------------------------------------

### Baseline Characterization {#s3_3_1}

After stratification analysis and PSM, 90 pairs of matched pairs were obtained. Among the surgery sample, 90 patients were in the salvianolate injection group and alprostadil injection group. There was a statistically significant difference in the distribution of nitrate esters in the two groups. At the same time, there was no statistically significant difference in the distribution of age, gender, medical institution level, region, comorbidities, other drug combination, and whether or not CHD-related surgery was performed (as shown in [**Table 4**](#T4){ref-type="table"}).

###### 

Baseline characteristics of the salvianolate injection group and the alprostadil injection group in the surgery sample.

  Variable                                   Total         Salvianolate injection group   Alprostadil injection group   *Z/χ^2^*   *P*                     
  ------------------------------------------ ------------- ------------------------------ ----------------------------- ---------- -------- ------- ------ --------
  Age, P~50~ (P~25~-P~75~)                   66 (59--72)   64 (59--72)                    68 (59--73)                   0.59       0.5535                  
  Gender                                                                                                                                            0.37   0.5428
   Male                                      108           60.0                           52                            57.8       56       62.2           
   Female                                    72            40.0                           38                            42.2       34       37.8           
  Level of medical institutions                                                                                                                     0.03   0.9852
   Tertiary hospital                         133           73.9                           66                            73.3       67       74.4           
   Secondary hospital                        45            25.0                           23                            25.6       22       24.4           
   Primary hospital                          2             1.1                            1                             1.1        1        1.1            
  Region                                                                                                                                            2.67   0.2636
   Eastern region                            108           60.0                           54                            60.0       54       60.0           
   Central region                            54            30.0                           30                            33.3       24       26.7           
   Western region                            18            10.0                           6                             6.7        12       13.3           
  Comorbidity                                                                                                                                       0.02   0.8793
   High blood pressure                       73            40.6                           36                            40.0       37       41.1           
   Heart failure                             21            11.7                           10                            11.1       11       12.2    0.05   0.8164
   Atrial fibrillation                       2             1.1                            1                             1.1        1        1.1     0.00   1.0000
   Heart valve disease                       1             0.6                            0                             0.0        1        1.1     1.01   0.3160
   Stroke                                    16            8.9                            8                             8.9        8        8.9     0.00   1.0000
   Pulmonary embolism                        0             0.0                            0                             0.0        0        0.0     \\     
   COPD                                      0             0.0                            0                             0.0        0        0.0     \\     
   Chronic nephrosis                         5             2.8                            2                             2.2        3        3.3     0.21   0.6501
   Diabetes                                  72            40.0                           36                            40.0       36       40.0    0.00   1.0000
  Drug combination                                                                                                                                         
   Beta blockers                             112           62.2                           53                            58.9       59       65.6    0.85   0.3563
   Nitrate esters                            174           96.7                           84                            93.3       90       100.0   6.21   0.0127
   ACEI or ARB                               96            53.3                           45                            50.0       51       56.7    0.80   0.3700
   Calcium antagonist                        64            35.6                           27                            30.0       37       41.1    2.42   0.1194
   Antiplatelet/thrombolytic/anticoagulant   166           92.2                           81                            90.0       85       94.4    1.24   0.2656
   Lipid regulating agents                   160           88.9                           82                            91.1       78       86.7    0.90   0.3428
  Related surgery of CHD                     41            22.8                           23                            25.6       18       20.0    0.79   0.3742

### Single-Factor Analysis of Outcome Indicators {#s3_3_2}

In the surgery sample, average days per hospitalization in the salvianolate injection group was slightly lower than that in the alprostadil group, and the difference was statistically significant (*P* \< 0.05). There was no significant difference in the 10d rehospitalization rate, 30d rehospitalization rate, 90d rehospitalization rate, and medical cost per hospitalization between the two groups (as shown in [**Table 5**](#T5){ref-type="table"}).

###### 

Comparison of outcomes between the salvianolate injection group and the alprostadil injection group in the surgery sample.

  Variable                            Total       Salvianolate injection group   Alprostadil injection group   *Z/χ^2^*   *P*                                                     
  ----------------------------------- ----------- ------------------------------ ----------------------------- ---------- -------- --------- --------- --------- --------- ------ --------
  Average days of per hospital stay   9           7                              13                            9          6        11        10        7         14        2.07   0.0389
  10d rehospitalization rate, n (%)   0 (0.0)     0 (0.0)                        0 (0.0)                       \\                                                                 
  30d rehospitalization rate, n (%)   5 (2.8)     3 (3.3)                        2 (2.2)                       0.21       0.6501                                                  
  90d rehospitalization rate, n (%)   19 (10.6)   10 (11.1)                      9 (10.0)                      0.06       0.8083                                                  
  Medical cost per hospitalization    13542.4     8570.3                         39148.7                       12348.1    8047.8   45162.2   14167.3   10071.7   35914.0   0.89   0.3744

### Multi-Factor Analysis of Outcome Indicators {#s3_3_3}

Multiple linear regression models were applied to control potential confounding factors such as age, gender, medical institution level, and comorbidities. In the surgery sample, the average hospitalization days in the salvianolate injection group was 0.805 times as long as that in the alprostadil injection group, which means less than that in the alprostadil injection group, and the difference was statistically significant (*P* = 0.023).

Non-Surgery Sample: Salvianolate Injection and Danhong Injection {#s3_4}
----------------------------------------------------------------

### Baseline Characterization {#s3_4_1}

After stratification analysis and PSM, 485 pairs of matched pairs were obtained. Among the surgery sample, 485 patients were in the salvianolate injection group and Danhong injection group. There was a statistically significant difference in the distribution of whether comorbid with pulmonary embolism in the two groups. At the same time, there was no statistically significant difference in the distribution of age, gender, medical institution level, region, other comorbidities, drug combination (as shown in [**Table 6**](#T6){ref-type="table"}).

###### 

Baseline characteristics of the salvianolate injection group and Danhong injection group in the non-surgery sample.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                   Total         Salvianolate injection group   Danhong injection group   *Z/χ^2^*   *P*                    
  ------------------------------------------ ------------- ------------------------------ ------------------------- ---------- -------- ------ ------ --------
  Age, P~50~ (P~25~-P~75~)                   67 (59--76)   68 (60--76)                    67 (59--76)               −0.96      0.3393                 

  Gender                                                                                                                                       0.50   0.4783

   Male                                      443           45.7                           216                       44.5       227      46.8          

   Female                                    527           54.3                           269                       55.5       258      53.2          

  Level of medical\                                                                                                                            0.04   0.9800
  institutions                                                                                                                                        

   Tertiary hospital                         435           44.9                           219                       45.2       216      44.5          

   Secondary hospital                        440           45.4                           219                       45.2       221      45.6          

   Primary hospital                          95            9.8                            47                        9.7        48       9.9           

  Region                                                                                                                                       2.47   0.2903

   Eastern region                            374           38.6                           176                       36.3       198      40.8          

   Central region                            516           53.2                           265                       54.6       251      51.8          

   Western region                            80            8.3                            44                        9.1        36       7.4           

  Comorbidity                                                                                                                                         

   High blood pressure                       224           23.1                           120                       24.7       104      21.4   1.49   0.2228

   Heart failure                             56            5.8                            33                        6.8        23       4.7    1.90   0.1686

   Atrial fibrillation                       22            2.3                            9                         1.9        13       2.7    0.74   0.3883

   Heart valve disease                       1             0.1                            0                         0.0        1        0.2    1.00   0.3171

   Stroke                                    50            5.2                            29                        6.0        21       4.3    1.35   0.2454

   Pulmonary embolism                        4             0.4                            0                         0.0        4        0.8    4.02   0.0451

   COPD                                      7             0.7                            2                         0.4        5        1.0    1.30   0.2551

   Chronic nephrosis                         12            1.2                            7                         1.4        5        1.0    0.34   0.5613

   Diabetes                                  200           20.6                           100                       20.6       100      20.6   0.00   1.0000

  Drug combination                                                                                                                                    

   Beta blockers                             437           45.1                           215                       44.3       222      45.8   0.20   0.6515

   Nitrate esters                            696           71.8                           336                       69.3       360      74.2   2.93   0.0870

   ACEI or ARB                               434           44.7                           219                       45.2       215      44.3   0.07   0.7962

   Calcium antagonist                        347           35.8                           185                       38.1       162      33.4   2.37   0.1234

   Antiplatelet/thrombolytic/anticoagulant   473           48.8                           229                       47.2       244      50.3   0.93   0.3353

   Lipid regulating agents                   725           74.7                           373                       76.9       352      72.6   2.41   0.1207
  ------------------------------------------------------------------------------------------------------------------------------------------------------------

### Single-Factor Analysis of Outcome Indicators {#s3_4_2}

In the non-surgical group, the average hospitalization duration in the salvianolate injection group was 9.2 ± 4.5 d, lower than that in the Danhong injection group (9.8 ± 4.8 d), and the difference was statistically significant (*P* \< 0.05) (as shown in [**Table 7**](#T7){ref-type="table"}).

###### 

Comparison of the outcomes of the salvianolate injection group and the Danhong injection group in the non-surgery sample.

  Variable                            Total      Salvianolate injection group   Danhong injection group   *Z/χ^2^*   *P*                                                  
  ----------------------------------- ---------- ------------------------------ ------------------------- ---------- -------- -------- -------- -------- -------- ------- --------
  Average days of per hospital stay   9          7                              12                        9          7        11       9        7        12       2.12    0.0340
  10d rehospitalization rate, n (%)   10 (1.0)   6 (1.2)                        4 (0.8)                   0.40       0.5249                                               
  30d rehospitalization rate, n (%)   22 (2.3)   13 (2.7)                       9 (1.9)                   0.74       0.3883                                               
  90d rehospitalization rate, n (%)   74 (7.6)   32 (6.6)                       42 (8.7)                  1.46       0.2265                                               
  Medical costs per hospitalization   6113.4     4514.9                         9104.3                    6056.7     4805.2   9038.0   6160.8   4119.0   9184.8   −1.75   0.0794

### Multi-Factor Analysis of Outcome Indicators {#s3_4_3}

Multiple linear regression models were used to control potential confounding factors such as age, gender, medical institution level, and comorbidities. There was no statistical difference (*P* = 0.199) in the days of hospitalization between the salvianolate group and the Danhong injection group in the non-surgery sample.

Non-Surgery Sample: Salvianolate Injection and Alprostadil Injection {#s3_5}
--------------------------------------------------------------------

### Baseline Characterization {#s3_5_1}

After stratification analysis and PSM, 169 pairs of matched pairs were obtained. Among the surgery sample, 169 patients were in the salvianolate injection group and alprostadil injection group. There was a statistically significant difference in the distribution of region, whether combined drugs with nitrate esters or antiplatelet/thrombolytic/anticoagulation, ACEI or ARB or calcium channel blockers between the two groups. At the same time, there was no statistically significant difference in the distribution of age, gender, medical institution level, region, comorbidities, other combined drugs that did not mentioned above (as shown in [**Table 8**](#T8){ref-type="table"}).

###### 

Baseline characteristics of salvianolate injection group and alprostadil injection group in the non-surgery sample.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                   Total         Salvianolate injection group   Alprostadil injection group   *Z/χ^2^*   *P*                      
  ------------------------------------------ ------------- ------------------------------ ----------------------------- ---------- -------- ------- ------- ----------
  Age, P~50~ (P~25~-P~75~)                   69 (62--78)   70 (61--79)                    69 (63--78)                   −0.38      0.7045                   

  Gender                                                                                                                                            2.68    0.1019

   Male                                      157           46.5                           71                            42.0       86       50.9            

   Female                                    181           53.6                           98                            58.0       83       49.1            

  Level of medical\                                                                                                                                 3.18    0.2043
  institutions                                                                                                                                              

   Tertiary hospital                         212           62.7                           113                           66.9       99       58.6            

   Secondary hospital                        104           30.8                           48                            28.4       56       33.1            

   Primary hospital                          22            6.5                            8                             4.7        14       8.3             

  Region                                                                                                                                            9.68    0.0079

   Eastern region                            204           60.4                           104                           61.5       100      59.2            

   Central region                            115           34.0                           62                            36.7       53       31.4            

   Western region                            19            5.6                            3                             1.8        16       9.5             

  Comorbidity                                                                                                                                               

   High blood pressure                       113           33.4                           51                            30.2       62       36.7    1.61    0.2047

   Heart failure                             31            9.2                            19                            11.2       12       7.1     1.74    0.1871

   Atrial fibrillation                       12            3.6                            5                             3.0        7        4.1     0.35    0.5566

   Heart valve disease                       1             0.3                            0                             0.0        1        0.6     1.00    0.3166

   Stroke                                    18            5.3                            8                             4.7        10       5.9     0.23    0.6280

   Pulmonary embolism                                      0.0                                                          0.0                 0.0             

   COPD                                      3             0.9                            0                             0.0        3        1.8     3.03    0.0819

   Chronic nephrosis                         3             0.9                            1                             0.6        2        1.2     0.34    0.5620

   Diabetes                                  100           29.6                           43                            25.4       57       33.7    2.78    0.0952

  Drug combination                                                                                                                                          

   Beta blockers                             178           52.7                           87                            51.5       91       53.9    0.19    0.6630

   Nitrate esters                            282           83.4                           113                           66.9       169      100.0   67.12   \<0.0001

   ACEI or ARB                               178           52.7                           80                            47.3       98       58.0    3.85    0.0499

   Calcium antagonist                        154           45.6                           68                            40.2       86       50.9    3.86    0.0493

   Antiplatelet/thrombolytic/anticoagulant   210           62.1                           91                            53.9       119      70.4    9.86    0.0017

   Lipid regulating agents                   269           79.6                           136                           80.5       133      78.7    0.16    0.6856
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------

### Single-Factor Analysis of Outcome Indicators {#s3_5_2}

In the non-surgery sample, medical cost per hospitalization in the salvianolate injection group was lower than that in the alprostadil group. Moreover, the days of hospitalization at a time in the salvianolate injection group was slightly lower than that in the alprostadil group, and the difference was statistically significant (*P* \< 0.05) (as shown in [**Table 9**](#T9){ref-type="table"}).

###### 

Comparison of outcomes between the salvianolate injection group and the alprostadil injection group in the non-surgery sample.

  Variable                            Total      Salvianolate injection group   Alprostadil injection group   *Z/χ^2^*   *P*                                                   
  ----------------------------------- ---------- ------------------------------ ----------------------------- ---------- -------- --------- -------- -------- --------- ------ --------
  Average days of per hospital stay   10         7                              14                            9          7        12        10       8        14        2.48   0.0130
  10d rehospitalization rate, n (%)   5 (1.5)    4 (2.4)                        1 (0.6)                       1.83       0.1765                                                
  30d rehospitalization rate, n (%)   9 (2.7)    6 (3.6)                        3 (1.8)                       1.03       0.3108                                                
  90d rehospitalization rate, n (%)   27 (8.0)   13 (7.7)                       14 (8.3)                      0.04       0.8410                                                
  Medical costs per hospitalization   8472.3     5629.2                         11734.7                       7718.7     5425.5   10616.4   9462.4   6037.9   12762.7   2.84   0.0045

### Multi-Factor Analysis of Outcome Indicators {#s3_5_3}

Multiple linear regression models were used to control potential confounding factors such as age, gender, medical institution level, and comorbidities. In the non-surgery sample, the days of per hospitalization of salvianolate injection group were 0.827 times that of the alprostadil group, which was lower than that of the alprostadil group, and the difference was statistically significant (*P* = 0.011). And in the non-surgery sample, the average hospitalization cost of the salvianolate injection group was 0.810 times that of the alprostadil group, which was lower than the alprostadil group, and the difference was statistically significant.

Discussion {#s4}
==========

This study focused on the clinical and economic evaluation of salvianolate injection, comparing with alprostadil injection and Danhong injection, which are commonly used in the treatment of CHD ([@B17]; [@B18]). In this study, we compared the two drugs with salvianolate injection through clinical and economic evaluation outcome indicators such as medical cost of hospitalization, days of hospital stay, and rehospitalization rate ([@B26]), to evaluate the drug economy and effectiveness of salvianolate injection in the real world. Because the data were not from controlled clinical trials, but from the real-world data, it can provide evidence for the effectiveness and economic effects ([@B40]). As real-world data can provide instructive information for clinical practice ([@B25]), the results of this study can provide a certain reference for the clinical practice of CHD.

However, real-world data also has certain defects and is prone to selection bias ([@B8]). Therefore, stratified analysis and PSM were used to reduce the impact of confounding factors on intervention effect estimation. The baseline situation between the study groups was more balanced and comparable than before ([@B27]). After PSM, stratified analysis, and multi-factor analysis, this study generated some significant findings that are worth further discussion as below.

Regarding hospitalization duration, it found that the hospitalization duration of salvianolate injection group was significantly shorter than that of Danhong injection group in the non-surgery sample. The hospitalization duration of salvianolate injection group was significantly shorter than those of alprostadil injection group in both surgery and non-surgery samples. Past research found that salvianolate injection was most frequently combined with clopidogrel and isosorbide dinitrate, and such combination showed higher clinical effectiveness as compared with other drug combinations ([@B3]). In particular, compared with conventional treatment for the treatment of CHD, the combination of salvianolate injection and conventional treatment was associated with a reduction in hospital stay ([@B9]). All of these findings show that clinical application of salvianolate injection has comparative advantages in reducing hospitalization stay of CHD patients.

Regarding medical cost per hospitalization, this study just found that the medical cost per hospitalization of salvianolate injection group was significantly (*P* \< 0.05) lower than that of alprostadil injection group in the non-surgery sample. As for CHD patients, surgery often accounts for most of the medical cost of hospitalization. Therefore, application of salvianolate injection can only show its economic advantages for CHD inpatients in non-surgery group when compared with alprostadil injection.

For rehospitalization rates, it found no significantly statistical differences in salvianolate injection group vs. alprostadil injection group or salvianolate injection group vs. Danhong injection group in both surgery and non-surgery samples. It has been indicated that the risk factors for rehabilitation of CHD patients can be much related to body composition ([@B4]). Such kind of results implies that drug therapies for CHD treatment needs more patient-centered exploration.

This study has several strengths. Firstly, this study was based on real-world data. By using real-world data, the clinical and economic evaluation of salvianolate injection for CHD was conducted, which can better show the actual clinical practice. Secondly, the data of this study was collected from the National Urban Basic Medical Insurance Database, which covered the whole nation, so the findings have more generalizing significance for CHD treatment. Thirdly, Peng et al. mentioned in their previous study of cost-consequence analysis of salvianolate injection for the treatment of CHD that their study did not stratify the severity of CHD due to the limitation of the original medical record ([@B9]). Therefore, this study considered the severity of the patient's disease on the results. Subgroups were carried out to analyze the injection of salvianolate and the other two contrast drugs in the surgery sample and the non-surgery sample, respectively, to make the results more authentic and reliable.

However, at the same time, there were some limitations, which are worth improving in future research. Firstly, since this study was a retrospective study, and the baseline variables provided were limited, potential confounders were difficult to control. Although stratified analysis and PSM were used, the interference of confounders and the selective bias cannot be eliminated entirely. Secondly, although the data of this study came from the National Urban Basic Medical Insurance Database, the sample size that met the rigor enrollment and medication conditions was relatively small, which led to the failure of multi-factor analysis of part of the rehospitalization rate. Thirdly, the data source in this study is unable to provide sufficient economic and effectiveness indicators due to its data limitations, which may lead to some bias to some extent. The prospective design of cost-effectiveness analysis is suggested for future evaluation of salvianolate injection.

Conclusion {#s5}
==========

Salvianolate injection showed advantages in reducing hospitalization duration for inpatients with CHD when comparing with alprostadil injection and Danhong injection. The results of this real-world study can help to inform prescription practice for CHD patients. More prospective investigation can be employed in future studies on the effectiveness of salvianolate injection.
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